You can narrow down the results using the filters
-
Cognitive impairment in patients with lymphoma
Expand descriptionThe purpose of this study is to assess the feasibility of collecting data on cognition over the course of treatment and recovery in patients with newly diagnosed aggressive lymphoma Who is it for? You may be eligible for this study if you are an adult who has been newly diagnosed with aggressive lymphoma, that is undergoing treatment at Austin Health. Study details All participants in this study will complete their usual treatment as prescribed by their doctor. Participants in this study will be assessed at three timepoints over the course of their treatment and recovery – one before treatment starts, one halfway, and one at the end of the treatment period. The assessment session will involve some tests to assess cognitive function and, in those participants willing to participate, a MRI brain scan and/or a PET/CT brain scan. It is hoped that this research will help determine if a larger study looking at cognitive function during chemotherapy for lymphoma is possible, adding to an underexplored area of cancer research.
-
Telerehabilitation and internet-based management of rotator cuff related pain: a pilot and feasibility randomised controlled trial
Expand description -
The DAFF Study – Direct Current Cardioversion for acute onset Atrial Fibrillation in the Emergency department and the need for Fentanyl.
Expand descriptionThis study aims to evaluate the need for Intravenous Fentanyl to provide Procedural analgesia during Direct Current Cardioversion for the treatment of acute onset Atrial fibrillation. Patents will be randomised to receive a pain relief medication (Fentanyl) or a placebo (Salt water) at the commencement of the procedure. All other elements of the procedure are the same. when the patient emerges and can state their name, the clinician will ask the patient to rank their perception of pain. This will be repeated at 10 minutes from the time the patient was able to state their name. The two groups will be compared to see if the patients receiving the Fentanyl rated their pain differently , to those that did not receive pain relief. This study aims to redefine and change clinical practice, avoid use of treatments when they are not indicated, improve patient safety by reducing harm from unnecessary treatments or interventions.
-
Genicular Nerve Block for Pain Management in Patients with Knee Osteoarthritis: A Randomised Double-blind Placebo Controlled Trial
Expand descriptionKnee Osteoarthritis affects many people, causing significant pain and immobility. At present, there are very few effective treatments available to managing pain in patients with osteoarthritis. This study is designed to investigate a new treatment, called a 'Genicular nerve block'. This study aims to demonstrate that 'Genicular nerve block' is a safe and effective method for treating knee osteoarthritis.
-
Group Based Acceptance and Commitment Therapy (ACT) for Improving Wellbeing following Primary Medical Intervention for Breast Cancer: A Follow-up Randomised Control Trial
Expand descriptionThe purpose of this study is to test the effect of Acceptance and Commitment Therapy on wellbeing. Who is it for? You may be eligible for this study if you are aged 18 or over, and have had treatment for breast cancer within the last 2 years. Study details Participants in this study will be randomised by chance (like flipping a coin) into two groups. One group (comparator) will continue treatment as usual, and will be able to access the intervention after a 3 month wait. The other group will immediately commence the intervention. The intervention, called Acceptance and Commitment Therapy involves six 90min group sessions, one session per week, with a psychologist. The intervention also involves some homework tasks between sessions. As part of the study, all participants will complete questionnaires. It is hoped that this study will contributed to improved quality of life in breast cancer survivors.
-
A Phase 2 study to evaluate the safety and tolerability of ACT001 in treating adults with Progressing Fibrosing Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF)
Expand descriptionThe current treatment options for patients with progressing Fibrosing Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) is limited and specific cohorts of patients cannot tolerate the approved treatments. Following the demonstration of activity in animal models for respiratory fibrotic diseases, this study will evaluate the safety and biological activity of ACT001 in adult patients. The study design will utilise a daily dose of ACT001, either alone or in combination with standard of care anti-fibrotic therapy, with evaluate safety, anti-inflammatory and anti-fibrotic activity in patients with stable disease state and evaluate any change in their respiratory function of a 12 month treatment period. The outcomes of this study are intended to support the biological activity of ACT001 so as to provide outcomes that can be translated into future research.
-
Preventing falls in mental health: a pilot RCT
Expand descriptionThe purpose of this study is to evaluate if a tailored fall prevention program can reduce falls, reduce the risk factors for falls and improve balance, strength, confidence and the home environment for older people with a mental illness living in the community. The intervention in this study will be adapted from the Stepping On fall prevention program, which has been shown to reduce falls in typical older people living in the community. By adapting this program to the needs of older people with a mental illness, we hypothesise that these adaptations will results in improved falls and other fall-related outcomes.
-
Imagery rescripting among young women at risk of developing an eating disorder
Expand descriptionThis study examined whether there is any superiority between two approaches to imagery rescripting (IR), namely rescripting disorder-specific negative body images into positive ones (i.e., body IR), or rescripting a past unpleasant experience associated with negative beliefs about self not specific to disordered eating (i.e., general IR), in a population of young women at risk of developing an eating disorder.
-
A validation trial of IBS.Mindovergut.com: A brief psychological online resilience program for individuals living with Irritable Bowel Syndrome (IBS) and low-to-moderate psychological distress.
Expand descriptionThe aim of the study is to explore the efficacy of the 4-week online IBS.Mindovergut.com resilience program for individuals living with irritable bowel syndrome and low to moderate psychological distress. The IBS.mindovergut.com resilience program is based on 5 modules (1 module per week), with the 5th module being optional. Each module (consisting of videos, text, handouts, and audio files e.g. relaxation tracks) is designed to be completed once a week, taking approximately 30 minutes, with associated homework-based activities taking a further 20-40 minutes per day. It is hypothesised that participants will report reduced IBS symptoms and increased quality of life.
-
A randomised, double-blind, placebo-controlled, phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of PMX205 in healthy volunteers.
Expand descriptionMotor neurone disease involves the destruction of the nerve cells that control your body’s movements. It is a progressive disease involving cells from the immune system attacking the nerve cells in the brain and spinal cord, which eventually causes death. The research project is testing the safety of a new drug called PMX205, which has been designed to interfere with how the body’s immune system attacks the brain. The purpose of this research is to determine if PMX205 is safe, if it affects the body as expected, and how much is in the blood after dosing. PMX205 will be injected under the skin in the top part of the abdomen. Alsonex Pty Ltd has shown that PMX205 can slow down the disease in animals and is safe to use. Medications, drugs and devices must be approved for use by the Australian Federal Government; the Therapeutic Goods Administration (TGA). PMX205 has not been approved for marketing by the TGA in Australia and is not yet approved anywhere else in the world. Therefore, the use of PMX205 in this study is experimental.